
Release date: 2026-01-07 17:23:55 Article From: Lucius Laos Recommended: 106
Ixazomib is a second-generation proteasome inhibitor that has emerged as a pivotal therapeutic option for the treatment of multiple myeloma.
Ixazomib is an oral proteasome inhibitor indicated for the treatment of multiple myeloma.[1] As the first oral second-generation proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA), it can be used in combination with dexamethasone and lenalidomide for patients who have received prior therapy, enabling a fully oral treatment regimen. This regimen has been proven to confer progression-free survival benefits. The approval of ixazomib was based on the results of the global phase III TOURMALINE-MM1 study, a double-blind, randomized trial conducted in patients with relapsed/refractory multiple myeloma.
Ixazomib is currently approved by the FDA for the treatment of relapsed or refractory multiple myeloma.
Ixazomib is sometimes used off-label for the treatment of amyloidosis.
Currently, ixazomib is also under investigation in a phase II clinical trial for patients with Waldenström’s macroglobulinemia. A number of ongoing studies are exploring the use of ixazomib in diseases such as bladder cancer, T-cell lymphoma, and neuroblastoma; however, these applications have not yet been approved.
Some adverse effects may be severe. Contact your doctor immediately if you experience any of the following symptoms:
Nausea, extreme fatigue, loss of appetite, flu-like symptoms, abnormal bleeding or bruising, yellowing of the skin or eyes, pain in the upper right abdomen, burning, tingling, numbness, pain or weakness in the arms or legs, as well as bloody stools or black, tarry stools.
In addition, ixazomib may cause other adverse effects. During treatment, consult your doctor promptly if you experience any unusual symptoms.
If the patient develops coma, seizures, difficulty breathing, or unresponsiveness, call emergency services immediately.
Keep all scheduled doctor appointments and laboratory tests. Your doctor will order specific laboratory tests to monitor your body’s response to ixazomib.
Maintain a written list of all prescription drugs, over-the-counter medications, vitamins, minerals, and dietary supplements you are taking. Bring this list with you to every doctor’s visit or hospital admission. It is recommended to carry the list with you at all times for emergency situations.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3012025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643